Cyclerion Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$1.20next fiscal year
Monitoring Framework
Key Performance Indicators
CYC-126 Phase 2 POC Trial Initiation QuarterlyTarget: Initiate Phase 2 proof-of-concept trial in Australia in 2H 2026
CYC-126 Phase 2 POC Patient Enrollment in the U.S. QuarterlyTarget: Commence patient enrollment in the U.S. in 1H 2027
Korsana Biosciences Merger Closing QuarterlyTarget: Complete reverse merger with Korsana Biosciences in Q3 2026
Watch Items
- Shareholder approval of the Korsana Biosciences merger and related proposals (reverse stock split, redomestication, share increase)Trigger: Shareholder vote scheduled for mid-2026Action: Monitor SEC filings for proxy voting results and S-4 amendment updates
- Closing of Korsana's $380 million pre-closing private financingTrigger: Conditioned upon and expected to close immediately prior to the mergerAction: Verify execution of the securities purchase agreement and receipt of gross proceeds
- Nasdaq confirmation of listing for the Combined Company (KRSA)Trigger: Customary closing condition for the mergerAction: Track Nasdaq listing status and ticker transition from CYCN to KRSA
Research as of 20 Jun 2026